Krystal Biotech said IOLITE enrollment for KB803 is complete and it remains on track for KB803 and KB801 registrational data readouts in 2026. The company also reported FDA platform technology designations for KB407 and KB111 and continued VYJUVEK expansion.
A Phase 3 trial shows administering immunochemotherapy before 3:00 PM improves survival outcomes in advanced NSCLC. Early treatment resulted in 11.3 months progression-free survival versus 5.7 months for late treatment, and 28.0 months overall survival versus 16.8 months. The findings suggest treatment timing is a modifiable factor that can enhance efficacy without additional cost.
The FDA is accelerating its review of daraxonrasib, a targeted therapy for pancreatic cancer, under a new pilot program that could reduce approval time from 10-12 months to one to two months.
Moffitt Cancer Center researchers published findings on plant-based diets and cancer risk, identified spatial tumor-immune patterns predicting immunotherapy response, and hosted a summit on engineering-driven cancer research innovations.
A prospective multicenter study found that baseline gut microbiome diversity selectively stratifies benefit from dual checkpoint blockade in advanced NSCLC, with high diversity associated with prolonged survival on immunotherapy alone while low diversity patients benefit from added chemotherapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07415005 |
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer |
RECRUITING | PHASE2 |
| NCT07392073 |
Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC |
NOT_YET_RECRUITING | |
| NCT07222566 |
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
RECRUITING | PHASE3 |
| NCT07105176 |
HS-IT101 Injection for Advanced NSCLC |
NOT_YET_RECRUITING | PHASE1 |
| NCT07090499 |
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT06980272 |
SSGJ-707 in Advanced Non-Small Cell Lung Cancer |
RECRUITING | PHASE3 |
| NCT06868732 |
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC |
RECRUITING | PHASE1 |
| NCT06823245 |
Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function |
NOT_YET_RECRUITING | PHASE1 |
| NCT06775483 |
Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study |
NOT_YET_RECRUITING | PHASE2 |
| NCT06761976 |
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation |
AVAILABLE |
